Sialylated glycan receptor

Sialylated glycan receptors are molecular structures—usually proteins or glycoproteins—that specifically recognize and bind sialic acid residues present on the terminal positions of cell-surface glycan chains. In mammals, the main family of endogenous sialylated glycan-binding receptors are the Siglecs, which function as immune checkpoints and participate in cellular signaling by distinguishing self from non-self[1][6][7]. Conversely, various pathogens (including viruses and bacteria) use specialized receptor proteins (e.g., viral hemagglutinins) to bind sialylated glycans on host cells, mediating infection[5][6]. Sialylated glycan–mediated interactions regulate numerous biological functions, including signal transduction, immune response, cell adhesion, cell migration, proliferation, and apoptosis[2][3][5][7]. Changes in cell-surface sialylation are associated with disease states such as cancer (hypersialylation as a tumor marker), infection (sialic acid dependence for viral entry), and inflammatory diseases[1][3][5][7]. Drugs targeting these receptors primarily aim to block pathogen attachment or modulate immune activity[5][6]. Common therapeutic challenges include balancing immune modulation with unintended effects on normal physiological sialylation[1][5].

Other names

Sialic acid binding receptorSialic acid binding proteinSialic acid-binding immunoglobulin-like lectin (Siglec, specifically for the protein family)Sialic acid-binding lectin

Inhibition of sialic acid–receptor binding (preventing viral/bacterial entry) - Modulation of immune checkpoint via Siglec targeting - Disruption of sialylation chemistry (e.g., by sialidase, affecting cell–cell interactions)